Update on management of ovarian hyperstimulation syndrome

Taiwanese Journal of Obstetrics and Gynecology

Volumn 50, Issue 1, 2011, Pages 2-10

  Chen, Chin Der ^a,b   Wu, Ming Ying ^a,b   Chao, Kuang Han ^a,b   Lien, Yih Ron ^a,b   Chen, Shee Uan ^a,b   Yang, Yu Shih ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Abdominal compartment syndrome; Dopamine agonist; Intra abdominal pressure; Ovarian hyperstimulation syndrome; Paracentesis

Indexed keywords

ALBUMIN; CABERGOLINE; DALTEPARIN; DIURETIC AGENT; DOCARPAMINE; DOPAMINE; DOXYCYCLINE; ENOXAPARIN; FUROSEMIDE; GANIRELIX; GONADORELIN ANTAGONIST; HEPARIN; OPIATE; PARACETAMOL; QUINAGOLIDE; SODIUM CHLORIDE; VASCULOTROPIN;

ABDOMINAL COMPARTMENT SYNDROME; ABSENCE OF SIDE EFFECTS; ASCITES; ASPIRATION; CLASSIFICATION; COLLOID; CRYSTALLOID; DIURETIC THERAPY; FLUID INTAKE; HEMODYNAMICS; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTRAVENOUS ADMINISTRATION; NONHUMAN; OUTPATIENT; OVARY HYPERSTIMULATION; PARACENTESIS; PATHOPHYSIOLOGY; PROPHYLAXIS; REVIEW; THROMBOEMBOLISM; THROMBOSIS PREVENTION;

COMPARTMENT SYNDROMES; FEMALE; HUMANS; MORBIDITY; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION;

EID: 79953801381     PISSN: 10284559     EISSN: 10284559     Source Type: Journal    
DOI: 10.1016/j.tjog.2011.01.014     Document Type: Review

References (79)

1. Madill J.J., Mullen N.B., Harrison B.P. Ovarian hyperstimulation syndrome: a potentially fatal complication of early pregnancy. J Emerg Med 2008, 35:283-286.
2. Chen C.D., Wu M.Y., Chao K.H., Chen S.U., Ho H.N., Yang Y.S. Serum estradiol level and oocyte number in predicting severe ovarian hyperstimulation syndrome. J Formos Med Assoc 1997, 96:829-834.
3. Humaidan P., Quartarolo J., Papanikolaou E.G. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril 2010, 94:389-400.
4. Polishuk W.Z., Schenker J.G. Ovarian overstimulation syndrome. Fertil Steril 1969, 20:443-450.
5. Goldsman M.P., Pedram A., Dominguez C.E., Ciuffardi I., Levin E., Asch R.H. Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome. Fertil Steril 1995, 63:268-272.
6. Chen S.U., Chen C.D., Yang Y.S. Ovarian hyperstimulation syndrome (OHSS): new strategies of prevention and treatment. J Formos Med Assoc 2008, 107:509-512.
7. Chen S.U., Chou C.H., Lee H., Ho C.H., Lin C.W., Yang Y.S. Lysophosphatidic acid up-regulates expression of interleukin-8 and -6 in granulosa-lutein cells through its receptors and nuclear factor-κB dependent pathways: implications for angiogenesis of corpus luteum and ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2008, 93:935-943.
8. Chen S.U., Chen R.J., Shieh J.Y., Chou C.H., Lin C.W., Lu H.F., et al. Human chorionic gonadotropin up-regulates expression of myeloid cell leukemia-1 protein in human granulosa-lutein cells: implication of corpus luteum rescue and ovarian hyperstimulation syndrome. J Clin Endocrinol Metab 2010, 95:3982-3992.
9. Dinarello C.A., Gelfand J.A., Wolff S.M. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993, 269:1829-1835.
10. McClure N., Healy D.L., Rogers P.A.W., Sullivan J., Beaton L., Haning R.V., et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994, 344:235-236.
11. Wang T.H., Horng S.G., Chang C.L., Wu H.M., Tsai Y.J., Wang H.S., et al. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 2002, 87:3300-3308.
12. Chen C.D., Chen H.F., Lu H.F., Chen S.U., Ho H.N., Yang Y.S. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 2000, 15:1037-1042.
13. Chen C.D., Wu M.Y., Chen H.F., Chen S.U., Ho H.N., Yang Y.S. Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome. Fertil Steril 1999, 72:286-292.
14. Chen S.U., Chou C.H., Lin C.W., Lee H., Wu J.C., Lu H.F., et al. Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways. Hum Reprod 2010, 25:757-767.
15. Chen C.D., Wu M.Y., Chen H.F., Chen S.U., Ho H.N., Yang Y.S. Relationships of serum pro-inflammatory cytokines and vascular endothelial growth factor with liver dysfunction in severe ovarian hyperstimulation syndrome. Hum Reprod 2000, 15:66-71.
16. Chan W.S. The 'ART' of thrombosis: a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol 2009, 21:207-218.
17. Carlotti A.P., Carvalho W.B. Abdominal compartment syndrome: a review. Pediatr Crit Care Med 2009, 10:115-120.
18. Selgas R., Del Peso G., Bajo M.A. Intra-abdominal hypertension favors ascites. Perit Dial Int 2010, 30:156-157.
19. Cheatham M.L. Abdominal compartment syndrome: pathophysiology and definitions. Scand J Trauma Resusc Emerg Med 2009, 17:10.
20. Harman P.K., Kron I.L., McLachlan H.D., Freedlender A.E., Nolan S.P. Elevated intra-abdominal pressure and renal function. Ann Surg 1982, 196:594-597.
21. Vlahos N.F., Gregoriou O. Prevention and management of ovarian hyperstimulation syndrome. Ann N Y Acad Sci 2006, 1092:247-264.
22. Hsieh M.J., Tsao T.C., Cheng P.J. Ovarian hyperstimulation syndrome with minimal ascites and massive pleural effusion: report of a case. J Formos Med Assoc 1994, 93:882-884.
23. Tang H.H., Tsai Y.C., Kang C.Y., Chung M.T., Loo T.C., Huang K.F. Atypical ovarian hyperstimulation syndrome with isolated pleural effusion but without ascites or hemoconcentration. Taiwan J Obstet Gynecol 2007, 46:180-182.
24. Beji O., Brahmi N., Thabet H., Mokline A., Abidi N., Blel Y., et al. Compressive pleural effusion after ovarian hyperstimulation syndrome-a case report and review. Fertil Steril 2008, 89:1826.e1-1826.e3.
25. Malbrain M., Cheatham M., Kirkpatrick A., Sugrue M., Parr M., De Waele J., et al. Results from the international conference of experts on intra-abdominal hypertension and abdominal compartment syndrome. I. Definitions. Intensive Care Med 2006, 32:1722-1732.
26. Cheatham M.L. Abdominal compartment syndrome. Curr Opin Crit Care 2009, 15:154-162.
27. Grossman L.C., Michalakis K.G., Browne H., Payson M.D., Segars J.H. The pathophysiology of ovarian hyperstimulation syndrome: an unrecognized compartment syndrome. Fertil Steril 2010, 94:1392-1398.
28. Cil T., Tummon I.S., House A.A., Taylor B., Hooker G., Franklin J., et al. A tale of two syndromes: ovarian hyperstimulation and abdominal compartment. Hum Reprod 2000, 15:1058-1060.
29. Maslovitz S., Jaffa A., Eytan O., Wolman I., Many A., Lessing J.B., et al. Renal blood flow alteration after paracentesis in women with ovarian hyperstimulation. Obstet Gynecol 2004, 104:321-326.
30. Golan A., Ron-El R., Herman A., Soffer Y., Weinraub Z., Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989, 44:430-440.
31. Navot D., Bergh P.A., Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992, 58:249-261.
32. Golan A., Weissman A. A modern classification of OHSS. Reprod Biomed Online 2009, 19:28-32.
33. Ovarian hyperstimulation syndrome. Fertil Steril 2003, 80:1309-1314. Practice Committee of American Society for Reproductive Medicine.
34. Ovarian hyperstimulation syndrome. Fertil Steril 2008, 90:S188-S193. Practice Committee of American Society for Reproductive Medicine.
35. Mathur R.S., Akande A.V., Keay S.D., Hunt L.P., Jenkins J.M. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000, 73:901-907.
36. Lee K.H., Kim S.H., Jee B.C., Kim Y.J., Suh C.S., Kim K.C., et al. Comparison of clinical characteristics between early and late patterns in hospitalized patients with ovarian hyperstimulation syndrome. Fertil Steril 2010, 93:2274-2280.
37. Chen C.D., Chao K.H., Yang J.H., Chen S.U., Ho H.N., Yang Y.S. Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome. Fertil Steril 2003, 80:86-90.
38. Chen C.D., Wu M.Y., Yang J.H., Chen S.U., Ho H.N., Yang Y.S. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome. Fertil Steril 1997, 68:287-291.
39. Whelan J.G., Vlahos N.F. The ovarian hyperstimulation syndrome. Fertil Steril 2000, 73:883-896.
40. Cheatham M., Malbrain M., Kirkpatrick A., Sugrue M., Parr M., De Waele J., et al. Results from the international conference of experts on intra-abdominal hypertension and abdominal compartment syndrome. II. Recommendations. Intensive Care Med 2007, 33:951-962.
41. Cheatham M. Nonoperative management of intraabdominal hypertension and abdominal compartment syndrome. World J Surg 2009, 33:1116-1122.
42. The management of ovarian hyperstimulation syndrome 2006, Royal College of Obstetricians and Gynaecologists (RCOG), RCOG, London (UK), pp. 11. (Green-top guideline; no. 5).
43. Shrivastav P., Nadkarni P., Craft I. Day care management of severe ovarian hyperstimulation syndrome avoids hospitalization and morbidity. Hum Reprod 1994, 9:812-814.
44. Lincoln S.R., Opsahl M.S., Blauer K.L., Black S.H., Schulman J.D. Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization. J Assist Reprod Genet 2002, 19:159-163.
45. Smith L.P., Hacker M.R., Alper M.M. Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis. Fertil Steril 2009, 92:1953-1959.
46. Fluker M.R., Copeland J.E., Yuzpe A.A. An ounce of prevention: outpatient management of the ovarian hyperstimulation syndrome. Fertil Steril 2000, 73:821-824.
47. Csokmay J.M., Yauger B.J., Henne M.B., Armstrong A.Y., Queenan J.T., Segars J.H. Cost analysis model of outpatient management of ovarian hyperstimulation syndrome with paracentesis: " Tap early and often" versus hospitalization. Fertil Steril 2010, 93:167-173.
48. Victorino G.P., Newton C.R., Curran B. Effect of hypertonic saline on microvascular permeability in the activated endothelium. J Surg Res 2003, 112:79-83.
49. Strandvik G.F. Hypertonic saline in critical care: a review of the literature and guidelines for use in hypotensive states and raised intracranial pressure. Anaesthesia 2009, 64:990-1003.
50. Tan T.S., Tan K.H., Ng H.P., Loh M.W. The effects of hypertonic saline solution (7.5%) on coagulation and fibrinolysis: an in vitro assessment using thromboelastography. Anaesthesia 2002, 57:644-648.
51. Ayus J.C., Krothapalli R.K., Arieff A.I. Treatment of symptomatic hyponatremia and its relation to brain damage. A prospective study. N Engl J Med 1987, 317:1190-1195.
52. Hew-Butler T., Almond C., Ayus J.C., Dugas J., Meeuwisse W., Noakes T., et al. Consensus statement of the 1st International Exercise-Associated Hyponatremia Consensus Development Conference, Cape Town, South Africa 2005. Clin J Sport Med 2005, 15:208-213.
53. Kolsen-Petersen J.A., Nielsen J.O., Tonnesen E. Acid base and electrolyte changes after hypertonic saline (7.5%) infusion: a randomized controlled clinical trial. Scand J Clin Lab Invest 2005, 65:13-22.
54. Oda J.M.D., Ueyama M.M.D., Yamashita K.M.D., Inoue T.M.D., Noborio M.M.D., Ode Y.M.D., et al. Hypertonic lactated saline resuscitation reduces the risk of abdominal compartment syndrome in severely burned patients. J Trauma 2006, 60:64-71.
55. Chen C.D., Yang J.H., Chao K.H., Chen S.U., Ho H.N., Yang Y.S. Effects of repeated abdominal paracentesis on uterine and intraovarian haemodynamics and pregnancy outcome in severe ovarian hyperstimulation syndrome. Hum Reprod 1998, 13:2077-2081.
56. Ozgun M.T., Batukan C., Oner G., Uludag S., Aygen E.M., Sahin Y. Removal of ascites up to 7.5 liters on one occasion and 45 liters in total may be safe in patients with severe ovarian hyperstimulation syndrome. Gynecol Endocrinol 2008, 24:656-658.
57. Cabrera J., Falcon L., Gorriz E., Pardo M.D., Granados R., Quinones A., et al. Abdominal decompression plays a major role in early postparacentesis haemodynamic changes in cirrhotic patients with tense ascites. Gut 2001, 48:384-389.
58. Al-Ramahi M., Leader A., Claman P., Spence J. A novel approach to the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum Reprod 1997, 12:2614-2616.
59. Abuzeid M.I., Nassar Z., Massaad Z., Weiss M., Ashraf M., Fakih M. Pigtail catheter for the treatment of ascites associated with ovarian hyperstimulation syndrome. Hum Reprod 2003, 18:370-373.
60. Nelson S.M. Prophylaxis of VTE in women-during assisted reproductive techniques. Thromb Res 2009, 123:S8-S15.
61. Ou Y.C., Kao Y.L., Lai S.L., Kung F.T., Huang F.J., Chang S.Y., et al. Thromboembolism after ovarian stimulation: successful management of a woman with superior sagittal sinus thrombosis after IVF and embryo transfer: case report. Hum Reprod 2003, 18:2375-2381.
62. Ferraretti A.P., Gianaroli L., Diotallevi L., Festi C., Trounson A. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 1992, 7:180-183.
63. Tsunoda T., Shibahara H., Hirano Y., Suzuki T., Fujiwara H., Takamizawa S., et al. Treatment for ovarian hyperstimulation syndrome using an oral dopamine prodrug, docarpamine. Gynecol Endocrinol 2003, 17:281-286.
64. Basu S., Nagy J.A., Pal S., Vasile E., Eckelhoefer I.A., Bliss V.S., et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001, 7:569-574.
65. Gomez R., Gonzalez-Izquierdo M., Zimmermann R.C., Novella-Maestre E., Alonso-Muriel I., Sanchez-Criado J., et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006, 147:5400-5411.
66. Alvarez C., Marti-Bonmati L., Novella-Maestre E., Sanz R., Gomez R., Fernandez-Sanchez M., et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007, 92:2931-2937.
67. Alvarez C., Alonso-Muriel I., Garcia G., Crespo J., Bellver J., Simon C., et al. Implantation is apparently unaffected by the dopamine agonist cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007, 22:3210-3214.
68. Carizza C., Abdelmassih V., Abdelmassih S., Ravizzini P., Salgueiro L., Salgueiro P.T., et al. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008, 17:751-755.
69. Youssef M.A.F.M., van Wely M., Hassan M.A., Al-Inany H.G., Mochtar M., Khattab S., et al. Can dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysis. Hum Reprod Update 2010, 16:459-466.
70. Antonini A., Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007, 6:826-829.
71. Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007, 356:39-46.
72. Busso C., Fernandez-Sanchez M., Garcia-Velasco J.A., Landeras J., Ballesteros A., Munoz E., et al. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod 2010, 25:995-1004.
73. Kolibianakis E.M., Collins J., Tarlatzis B.C., Devroey P., Diedrich K., Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006, 12:651-671.
74. Friden B.E., Nilsson L. Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization. Acta Obstet Gynecol Scand 2005, 84:812-816.
75. Lainas T.G., Sfontouris I.A., Zorzovilis I.Z., Petsas G.K., Lainas G.T., Kolibianakis E.M. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online 2007, 15:408-412.
76. Rollene N.L., Amols M.H., Hudson S.B.A., Coddington C.C. Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series. Fertil Steril 2009, 92:1169.e15-1169.e17.
77. Moses M.A., Harper J., Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 2006, 354:2621-2622.
78. Fainaru O., Adini I., Benny O., Bazinet L., Pravda E., D'Amato R., et al. Doxycycline induces membrane expression of VE-cadherin on endothelial cells and prevents vascular hyperpermeability. FASEB J 2008, 22:3728-3735.
79. Fainaru O., Hornstein M.D., Folkman J. Doxycycline inhibits vascular leakage and prevents ovarian hyperstimulation syndrome in a murine model. Fertil Steril 2009, 92:1701-1705.